[go: up one dir, main page]

MX2017012510A - Combinaciones antihelminticas y metodos de uso de ellas. - Google Patents

Combinaciones antihelminticas y metodos de uso de ellas.

Info

Publication number
MX2017012510A
MX2017012510A MX2017012510A MX2017012510A MX2017012510A MX 2017012510 A MX2017012510 A MX 2017012510A MX 2017012510 A MX2017012510 A MX 2017012510A MX 2017012510 A MX2017012510 A MX 2017012510A MX 2017012510 A MX2017012510 A MX 2017012510A
Authority
MX
Mexico
Prior art keywords
methods
prophylaxis
treatment
macrocyclic lactone
anthelmintic
Prior art date
Application number
MX2017012510A
Other languages
English (en)
Other versions
MX381319B (es
Inventor
BONDESEN Brenda
Hammerland Lance
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of MX2017012510A publication Critical patent/MX2017012510A/es
Publication of MX381319B publication Critical patent/MX381319B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a una composición veterinaria que comprende una cantidad efectiva de por lo menos un depsipéptido cíclico y por lo menos una lactona macrocíclica; y un portador farmacéuticamente aceptable, para el tratamiento o profilaxis de infección parasítica en un mamífero en donde el parásito muestra resistencia al tratamiento o profilaxis con la lactona macrocíclica sola.
MX2017012510A 2015-04-02 2016-04-01 Combinaciones antihelmínticas y métodos de uso de ellas. MX381319B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562142304P 2015-04-02 2015-04-02
PCT/US2016/025714 WO2016161369A1 (en) 2015-04-02 2016-04-01 Anthelmintic combinations and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2017012510A true MX2017012510A (es) 2018-01-30
MX381319B MX381319B (es) 2025-03-12

Family

ID=57006415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012510A MX381319B (es) 2015-04-02 2016-04-01 Combinaciones antihelmínticas y métodos de uso de ellas.

Country Status (18)

Country Link
US (1) US10993988B2 (es)
EP (1) EP3277303B1 (es)
JP (1) JP6899330B2 (es)
KR (1) KR20170132330A (es)
CN (1) CN107567334A (es)
AU (1) AU2016244022A1 (es)
BR (1) BR112017020975A2 (es)
CA (1) CA2981489A1 (es)
CL (1) CL2017002474A1 (es)
CO (1) CO2017011284A2 (es)
ES (1) ES2851345T3 (es)
IL (1) IL254783B (es)
MX (1) MX381319B (es)
MY (1) MY187835A (es)
PH (1) PH12017501806A1 (es)
RU (1) RU2717545C2 (es)
SG (1) SG11201708008TA (es)
WO (1) WO2016161369A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018093920A1 (en) * 2016-11-16 2018-05-24 Merial, Inc. Anthelmintic depsipeptide compounds
HRP20230870T1 (hr) * 2017-02-08 2023-11-10 Boehringer Ingelheim Animal Health USA Inc. Model in vivo za infekciju parazitnim crvima i postupak ocjenjivanja antiparazitnih spojeva, uključujući spojeve koji djeluju protiv pseće dirofilarioze
EP3713567A1 (en) 2017-11-23 2020-09-30 Ceva Sante Animale Composition containing moxidectin for treating parasites infestations
SG11202003832WA (en) * 2017-11-29 2020-06-29 Zoetis Services Llc Endoparasitic depsipeptides
AR116524A1 (es) * 2018-10-04 2021-05-19 Elanco Tiergesundheit Ag Potenciación de tratamiento de helmintos
PE20250675A1 (es) 2021-11-01 2025-03-04 Boehringer Ingelheim Vetmedica Gmbh Compuestos de pirrolopiridazina como antihelminticos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134973A (en) 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
GB9300883D0 (en) 1993-01-18 1993-03-10 Pfizer Ltd Antiparasitic agents
DE19520275A1 (de) * 1995-06-02 1996-12-05 Bayer Ag Endoparasitizide Mittel
US20030129680A1 (en) 2001-10-31 2003-07-10 O'connor Thomas Patrick Multi-analyte assay device
US20070042354A1 (en) 2005-08-19 2007-02-22 Engelhard Eric K Detecting pathogens in companion animals
CA2678149C (en) * 2007-02-21 2013-04-16 Pfizer Limited Benzofuran antiparasitic agents
JP4734656B2 (ja) 2007-03-30 2011-07-27 国立大学法人群馬大学 Ｐｆ１０２２類の製造法
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
WO2010053517A2 (en) 2008-10-29 2010-05-14 Aroian Raffi V Combination therapy to combat helminth resistance
BE1019407A5 (nl) 2009-11-06 2012-07-03 Momentum Animal Cure Bvba Middel voor het uitdrijven van parasieten bij mensen, dieren en vogels.
US20120295931A1 (en) 2010-02-05 2012-11-22 Lutz Juergen Spiroindoline compounds for use as anthelminthics
WO2011115840A2 (en) 2010-03-14 2011-09-22 Ibis Biosciences, Inc. Parasite detection via endosymbiont detection
RU2452180C2 (ru) 2010-08-31 2012-06-10 Общество с ограниченной ответственностью "Научно-внедренческое предприятие "Астрафарм" Комплексная антипаразитарная композиция
AU2010101389C4 (en) 2010-12-08 2017-03-02 Jurox Pty Ltd Anthelmintic formulation
AU2010249226C1 (en) 2010-12-08 2017-04-13 Zoetis Services Llc Anthelmintic formulation
US9096599B2 (en) 2011-08-04 2015-08-04 Intervet Inc. Spiroindoline compounds

Also Published As

Publication number Publication date
RU2017138118A3 (es) 2019-07-24
IL254783B (en) 2020-11-30
BR112017020975A2 (pt) 2018-07-10
JP2018510195A (ja) 2018-04-12
CN107567334A (zh) 2018-01-09
PH12017501806A1 (en) 2018-04-11
ES2851345T3 (es) 2021-09-06
RU2717545C2 (ru) 2020-03-24
SG11201708008TA (en) 2017-10-30
KR20170132330A (ko) 2017-12-01
JP6899330B2 (ja) 2021-07-07
WO2016161369A1 (en) 2016-10-06
CO2017011284A2 (es) 2018-01-31
CL2017002474A1 (es) 2018-03-23
RU2017138118A (ru) 2019-05-06
EP3277303B1 (en) 2020-12-02
CA2981489A1 (en) 2016-10-06
US10993988B2 (en) 2021-05-04
MY187835A (en) 2021-10-26
US20170020955A1 (en) 2017-01-26
AU2016244022A1 (en) 2017-10-26
EP3277303A1 (en) 2018-02-07
MX381319B (es) 2025-03-12
IL254783A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
CO2017011284A2 (es) Combinaciones antihelmínticas y métodos de uso de ellas
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
MX385876B (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
CL2017003404A1 (es) Compuestos antibacterianos
MX2016009337A (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
MX2017007829A (es) Composicion antimicrobiana.
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
CL2014003509A1 (es) Composición veterinaria masticable blanda que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal (div. sol. n°2087-14).
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
CL2015001389A1 (es) Composiciones y compuestos antihelmínticos y métodos para usarlos.
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
CO2020000328A2 (es) Formulaciones a largo plazo
CL2015002744A1 (es) Alimento para peces que comprende azadiractina, útil para el tratamiento y/o prevención de infecciones y/o infestaciones parasitarias, particularmente contra el piojo de mar lepeophtherius salmonis.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer